• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a...
BEFORE Unretouched photos, taken in standard lighting. Results may vary. AFTER Unretouched photos, taken in standard lighting. Results may vary....
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big...
XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of...
ZUG, Switzerland and SAN JUAN, Puerto Rico, April 25, 2023 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted...
SOLANA BEACH, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...
Q1 Revenues of $30 million up 4% over prior year periodQ1 GAAP Operating Income of $1.7 million up from a...
PetVivo Holdings, Inc. Mary Grace Rutland - New Business Development Manager for the Mid-Atlantic Region of the United StatesMINNEAPOLIS, MN,...
TUCSON, Ariz., April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools...
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million...
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy clinics planned for opening by...
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions at 60 Seconds Results to...
First-ever orphan drug designation for genetically modified gamma-delta T cell therapiesThis orphan drug designation offers potential 7-year market exclusivity for...
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical...
Breakthrough platform creating multi-valent and multi-specific biotherapeutics with broad transformative applications Building innovative internal pipeline in oncology TORONTO, April 25,...
Three U.S. clinical trial sites actively screening and enrolling patientsTop line data of adrulipase in Cystic Fibrosis patients expected in...